A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax

Dec 19

Written By Maria Parshenkova

Download Poster

Maria Parshenkova

Therapeutic Targeting of FLT3 gate keeper mutation with E2082-0047 in traditional and a novel Immunocompetent murine adoptive transfer model of AML